Status:
NO_LONGER_AVAILABLE
Individual Patient Expanded Access IND of Hope Biosciences First Blood Relative Allogeneic Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Pancreatic Cancer
Lead Sponsor:
Hope Biosciences LLC
Conditions:
Pancreatic Cancer
Eligibility:
MALE
Brief Summary
The drug for this submission is Hope Biosciences' allogeneic, first blood relative, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Pancr...
Detailed Description
Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will return for the first infusion. Subsequent treatments will occur weekly for the first 8 i...
Eligibility Criteria
Inclusion
- Documented diagnosis of Pancreatic Cancer
- Hemodynamically stable
Exclusion
- Immunosuppression as defined by WBC \< 3, 000 cells/ml at baseline screening.
- Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration.
- Any abnormal, inexplicable laboratory result with no obvious cause defined.
- Participation in other interventional research studies. Unwillingness to return for follow-up visits
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04087889
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hope Biosciences
Sugar Land, Texas, United States, 77478